Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04268888
Title Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3)
Acronym TACE-3
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Clatterbridge Cancer Centre NHS Foundation Trust
Age Groups: child | senior | adult
Covered Countries GBR

No variant requirements are available.